Loading
A phase 2 trial of Budigalimab, Livmoniplimab, Lenvatinib in hepatocellular carcinoma, run by AbbVie, active and no longer recruiting.
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) is a phase 2 interventional study registered as NCT05822752 by AbbVie, with 130 participants enrolled, started 2023-09-21 and due to reach its primary completion in 2026-11. Interventions recorded: Budigalimab, Livmoniplimab, Lenvatinib, Sorafenib. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Budigalimab, Livmoniplimab, Advanced hepatocellular carcinoma (BCLC C), AbbVie (incl. ImmunoGen, Capstan).
Shares Budigalimab, Livmoniplimab, AbbVie (incl. ImmunoGen, Capstan).
Shares Budigalimab, Livmoniplimab, AbbVie (incl. ImmunoGen, Capstan).
Shares Sorafenib, Advanced hepatocellular carcinoma (BCLC C), Lenvatinib.
Shares Sorafenib, Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Lenvatinib, Hepatocellular carcinoma.
Shares Sorafenib, Advanced hepatocellular carcinoma (BCLC C), Lenvatinib, Hepatocellular carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/